Table 2

Titers and specificities of FVIII-binding antibodies and results of FVIII inhibitor assays

Study cohort/identification codeAntibody titer against FVIIIBinding to BDD FVIIICompetition by FVIIIFVIII inhibitors, (BU/mL)
Healthy     
    Healthy 67 1:320 No Yes < 0.6 
    Healthy 549 1:160 No Yes < 0.6 
    Healthy 226 1:80 No Yes < 0.6 
    Healthy 262 1:80 No Yes < 0.6 
    Healthy 510 1:80 Yes Yes < 0.6 
    Healthy 304 1:80 No Yes < 0.6 
    Healthy 480 1:80 No Yes < 0.6* 
    Healthy 79 1:320 No Yes < 1.0* 
    Healthy 217 1:80 No Yes < 0.6 
    Healthy 512 1:160 No Yes < 1.0* 
    Healthy 20 1:80 No Yes < 0.6 
    Healthy 398 1:80 No Yes < 0.6 
    Healthy 62 1:80 No Yes < 0.6 
    Healthy 282 1:80 No Yes < 0.6 
HA-noINH     
    HA-noINH 7 1:320 No Yes < 0.6 
    HA-noINH 13 1:80 No Yes < 0.6 
    HA-noINH 52 1:80 No Yes < 0.6 
    HA-noINH 77 1:80 No Yes < 0.6 
HA-ITI     
    HA-ITI 5 1:80 No Yes < 0.6 
Study cohort/identification codeAntibody titer against FVIIIBinding to BDD FVIIICompetition by FVIIIFVIII inhibitors, (BU/mL)
Healthy     
    Healthy 67 1:320 No Yes < 0.6 
    Healthy 549 1:160 No Yes < 0.6 
    Healthy 226 1:80 No Yes < 0.6 
    Healthy 262 1:80 No Yes < 0.6 
    Healthy 510 1:80 Yes Yes < 0.6 
    Healthy 304 1:80 No Yes < 0.6 
    Healthy 480 1:80 No Yes < 0.6* 
    Healthy 79 1:320 No Yes < 1.0* 
    Healthy 217 1:80 No Yes < 0.6 
    Healthy 512 1:160 No Yes < 1.0* 
    Healthy 20 1:80 No Yes < 0.6 
    Healthy 398 1:80 No Yes < 0.6 
    Healthy 62 1:80 No Yes < 0.6 
    Healthy 282 1:80 No Yes < 0.6 
HA-noINH     
    HA-noINH 7 1:320 No Yes < 0.6 
    HA-noINH 13 1:80 No Yes < 0.6 
    HA-noINH 52 1:80 No Yes < 0.6 
    HA-noINH 77 1:80 No Yes < 0.6 
HA-ITI     
    HA-ITI 5 1:80 No Yes < 0.6 

Titers and specificities of FVIII-binding antibodies and results of FVIII inhibitor assays found in healthy individuals and in hemophilia A patients without FVIII inhibitors. All cases with titers ≥ 1:80 are included.

FVIII indicates factor VIII; HA-noINH, hemophilia A patients without inhibitors; and A-ITI, hemophilia A patients after successful immune tolerance induction therapy (ITI).

*

Samples were tested in-house with a commercially available kit.

or Create an Account

Close Modal
Close Modal